Skip to main content

Advertisement

SpringerLink
Log in

Synergistic effect of a retinoid X receptor-selective ligand bexarotene (LGD1069, Targretin) and paclitaxel (Taxol) in mammary carcinoma

  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

We have previously shown that the retinoid X receptor (RXR) ligand bexarotene (LGD1069, Targretin) is efficacious as a chemopreventive and chemotherapeutic agent in rat N-nitroso-N-methylurea (NMU)-induced mammary carcinomas (Cancer Res 58: 479–484, 1998). To determine additional role for bexarotene in breast cancer treatment, we evaluated the effect of bexarotene on the efficacy of paclitaxel (Taxol) treatment in a rat NMU-derived mammary tumor cell line, NMU-417,in vitro and in rat NMU-induced mammary tumors in vivo. Our growth inhibition results showed that the bexarotene/paclitaxel combination produced a concentration-dependent synergy in NMU-417 tumor cell line. Synergistic growth inhibition by the combination was associated with an increase in cell death induced by both agents. In rat NMU-induced mammary tumor model in vivo, the benefit of combination therapy was observed as early as 1 week after treatment and increased as treatment continued. At the end of 6 weeks of treatment, the bexarotene/paclitaxel combination produced an overall objective response rate of 94% compared with a rate of 12% in paclitaxel-treated and 58% in bexarotene-treated animals, an effect that was more than the additive effects produced by single agents. Although both bexarotene alone and the bexarotene/paclitaxel combination reduced tumor multiplicity to similar extent, the combination regimen produced a statistically significant decrease in total tumor burden compared to single agents and untreated controls (two-tailed, p > 0.05). Combination therapy did not further alter body weight nor increase toxicity when compared to single agents. In summary, our results demonstrated the potential of using a RXR selective ligand in combination with chemotherapy for the treatment of breast cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Harn SM, Liebman JE, Cook J, Fisher J, Goldspiel B, Venzon D, Mitchell JB, Kaufman D: Taxol in combination with doxorubicin or etoposide. Cancer 72: 2705–2711, 1993

    Google Scholar 

  2. Tolcher AW: Paclitaxel couplets with cyclophosphamide or cisplatin in metastatic breast cancer. Semin Oncol 23 (Suppl 1): 37–43, 1996

    Google Scholar 

  3. Fornier M, Esteva FJ, Seidman AD: Trastuzumab in combination with chemotherapy for the treatment of metastatic breast cancer. Semin Oncol 27 (6 Suppl 11): 38–45, 2000

    Google Scholar 

  4. Horwitz SB, Cohen D, Rao S, Ringel I, Shen HJ, Yang CP: Taxol: mechanisms of action and resistance. J Natl Cancer Inst Monogr 15: 55–61, 1993

    Google Scholar 

  5. Sangrajrang S, Fellous A: Taxol Resistance. Chemotherapy 46: 327–334, 2000

    Google Scholar 

  6. Holmes FA, Walters RS, Theriault RL, et al: Phase II trial of Taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 83: 1797–1805, 1991

    Google Scholar 

  7. Boehm MF, Zhang L, Badea BA, White SK, Mais DE, Berger E, Suto CM, Goldman ME, Heyman RA: Synthesis and structure-activity relationships of novel retinoid X receptor-selective retinoids. J Med Chem 37: 2930–2941, 1994

    Google Scholar 

  8. Gottardis MM, Bischoff ED, Shirley MA, Wagoner MA, Lamph WW, Heyman RA: Chemprevention of mammary carcinoma by LGD1069 (Targretin): an RXR-selective ligand. Cancer Res 56: 5566–5570, 1996

    Google Scholar 

  9. Wu K, Zhang Y, Xu X-C, Hill J, Celestino J, Kim H-T, Mohsin SK, Hilsenbeck SG, Lamph WW, Bissonnette R, Brown PH: The retinoid X receptor-selective retinoid, LGD1069, prevents the development of estrogen receptor-negative mammary tumors in transgenic mice. Cancer Res 62: 6376–6380, 2002

    Google Scholar 

  10. Wu K, Kim H-T, Rodriquez JL, Hilsenbeck SG, Mohsin SK, Xu X-C, Lamph WW, Kuhn JG, Green JE, Brown PH: Suppression of mammary tumorigenesis in transgenic mice by the RXR-selective retinoid, LGD1069. Cancer Epid Biomarker Prevention 11: 467–474, 2003

    Google Scholar 

  11. Bischoff ED, Gottardis MM, Moon TE, Heyman RA, Lamph WW: Beyond tamoxifen: the retinoid X receptorselective ligand LGD1069 (Targretin) causes complete regression of mammary carcinoma. Cancer Res. 58: 479–484, 1998

    Google Scholar 

  12. Bischoff ED, Heyman RA, Lamph WW: Effect of the retinoid X receptor-selective ligand LGD1069 on mammary carcinoma after tamoxifen failure. J Natl Cancer Inst 91: 2118–2123, 1999

    Google Scholar 

  13. Agarwal VR, Bischoff ED, Hermann T, Lamph WW: Induction of adipocyte-specific gene expression is correlated with mammary tumor regression by the retinoid X receptorligand LGD1069 (Targretin). Cancer Res 60: 6033–6038, 2000

    Google Scholar 

  14. Duvic M, Hymes K, Heald P, Breneman D, Martin AG, Myskowski P, Crowley C, Yocum RC: Bexarotene is effective and safe for treatment of refractory advancedstage cutaneous T-cell lymphoma: multinational phase II–III trail results. J Clin Oncology 19: 2456–2471, 2001

    Google Scholar 

  15. Chou TC, Talalay P: Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27–55, 1984

    Google Scholar 

  16. Chou TC: The median-effect principle and the combination index for quantitation of synergism and antagonism. In: Chou TC, Rideout DC (eds) Synergism and Antagonism in Chemotherapy. Academic Press, NY, 1991, pp 61–102

    Google Scholar 

  17. Blagosklonny MV, Schulte T, Nguyen P, Trepel J, Nechers LM: Taxol-induced apoptosis and phosphorylation of bcl-2 protein involves c-raf-1 and represents a novel c-raf-1 signal transduction pathway. Cancer Res. 56: 1851–1854, 1996

    Google Scholar 

  18. Lee LF, Li G, Templeton DJ, Ting JP-Y: Paclitaxel (Taxol)-induced gene expression and cell death are both mediated by the activation of c-jun NH2-terminal kinase (JNK/SAPK). J Biol Chem 273: 28253–28260, 1998

    Google Scholar 

  19. Vivat-hannah V, You D, Rizzo C, Daris J-P, Lapointe P, Zusi C, Marinier A, Lorenzi MV, Gottardis MM: Synergistic cytotoxicity exhibited by combination treatment of selective retinoid ligands with Taxol (paclitaxel). Cancer Res 61: 8703–8711, 2001

    Google Scholar 

  20. Yen A, Roberson MS, Varvayanis S, Lee AT: Retinoic acid induced mitogen-activated protein (MAP)/extracellular signal-regulated kinase (ERK) kinase-dependent MAT kinase activation needed to elicit HL-60 cell differentiation and growth arrest. Cancer Res 58: 3163–3172, 1998

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Molecular Oncology, Ligand Pharmaceuticals Inc., San Diego, CA, 92121, USA

    Wan-ching Yen, Rene Y. Prudente & William W. Lamph

Authors
  1. Wan-ching Yen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rene Y. Prudente
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. William W. Lamph
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yen, Wc., Prudente, R.Y. & Lamph, W.W. Synergistic effect of a retinoid X receptor-selective ligand bexarotene (LGD1069, Targretin) and paclitaxel (Taxol) in mammary carcinoma. Breast Cancer Res Treat 88, 141–148 (2004). https://doi.org/10.1007/s10549-004-1426-5

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-004-1426-5

Search

Navigation